ArticleBritish journal of pharmacology2019
Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05044936 (The Effects of Topical Cannabidiol Cream on Post-exercise Recovery), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Topical Cannabidiol Cream on Post-exercise Recovery
Who cites it
42 citing papers in PubMed, 77 citations in OpenAlex.
- Cannabigerol Enhances Muscle Strength and Performance in Dexamethasone-Treated Mice.ACS pharmacology & translational science · 2026Article
- Endocannabinoid system and skeletal muscle health: Insights from cannabidiol.Molecular metabolism · 2026Review
- Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways.Acta pharmaceutica Sinica. B · 2026Review
- Topical application of cannabidiol for muscle recovery after exercise-induced muscle damage: a randomized, double-blinded pilot study.Journal of cannabis research · 2026Article
- Loss of dystrophin reduces CB1 receptor expression and endocannabinoid-dependent synaptic plasticity in the cerebellar cortex.bioRxiv : the preprint server for biology · 2026Article
- Muscular Dystrophy Muscle Preservation: A Comparative Systematic Review of Exercise and Cannabidiol (CBD) Interventions.Journal of biotechnology and biomedicine · 2026Article
- Cannabidiol reshapes the gut microbiome to promote endurance exercise in mice.Experimental & molecular medicine · 2025Article
- Histone deacetylase 6 inhibition promotes microtubule acetylation and facilitates autophagosome-lysosome fusion in dystrophin-deficient mdx mice.Acta physiologica (Oxford, England) · 2025Article
- Dual Role of TRPV1 Channels in Cerebral Stroke: An Exploration from a Mechanistic and Therapeutic Perspective.Molecular neurobiology · 2024Review
- Comparative transcriptomics of broad-spectrum and synthetic cannabidiol treated C2C12 skeletal myotubes.Physiological reports · 2024Article
- Cannabinoids, Endocannabinoids, and Synthetic Cannabimimetic Molecules in Neuromuscular Disorders.International journal of molecular sciences · 2023Review
- Dysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin.Cell death & disease · 2023Article
- Comparative evaluation of ethyl acetate and n-Hexane extracts ofFood science & nutrition · 2023Article
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis.Scientific reports · 2023Article
- Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance.Antioxidants (Basel, Switzerland) · 2023Review
- Cannabidiol Does Not Impact Acute Anabolic or Inflammatory Signaling in Skeletal MuscleCannabis and cannabinoid research · 2022Article
- Article
- The TRPV1 Receptor Is Up-Regulated by Sphingosine 1-Phosphate and Is Implicated in the Anandamide-Dependent Regulation of Mitochondrial Activity in C2C12 Myoblasts.International journal of molecular sciences · 2022Article
- Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeDuchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo. EXPERIMENTAL APPROACH: Using quantitative PCR, western blots and [Ca KEY
resultsCBD and CBDV promoted the differentiation of murine C2C12 myoblast cells into myotubes by increasing [Ca CONCLUSION AND IMPLICATIONS: We provide new insights into plant cannabinoid interactions with TRP channels in skeletal muscle, highlighting a potential opportunity for novel co-adjuvant therapies to prevent muscle degeneration in DMD patients. LINKED ARTICLES: This article is part of a themed section on 8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.